Stay updated with breaking news from Cll. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This interview will appear in the January 2024 issue of Evidence-Based Oncology.™ Each year, our January issue features a recap of proceedings from the American Society of Hematology Meeting and Exposition.
The top stories on chronic lymphocytic leukemia from 2023 included topics like BTK inhibitors, minimal residual disease status and approaches to care for various stages of the disease.
Nicole Lamanna, MD, discusses the results from the ongoing BGB-11417-101 study investigating combination zanubrutinib plus sonrotoclax in patients with treatment-naïve CLL/SLL.
Constantine S. Tam, MD, MBBS, presents the biomarker subgroup analysis from the phase 3 SEQUOIA study investigating zanubrutinib in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma without del(17p).